NASDAQ: OTLK
Outlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?

Insider buying vs selling

Have Outlook Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ghiath M. SukhtianDirector2026-08-122,525,252$0.99
$2.50MBuy
Faisal Ghiath SukhtianDirector2026-07-2995,398$1.05
$99.98kBuy
Yezan Munther HaddadinDirector2026-06-0229,000$0.83
$24.16kBuy
Ghiath M. SukhtianDirector2026-05-288,539,709$0.59
$5.00MBuy
Faisal Ghiath SukhtianDirector2026-05-27122,174$0.41
$49.97kBuy
Randy H. ThurmanDirector2026-05-265,000$0.43
$2.15kBuy
Kurt J. HilzingerDirector2026-05-26400,000$0.44
$176.40kBuy
Yezan Munther HaddadinDirector2026-05-2634,000$0.44
$14.96kBuy

1 of 1

OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OTLK insiders and whales buy or sell their stock.

OTLK Shareholders

What type of owners hold Outlook Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ghiath M. Sukhtian47.96%116,756,592$50.91MInsider
Faisal Ghiath Sukhtian23.02%56,037,758$24.43MInsider
Biolexis Pte Ltd10.45%25,443,159$11.09MInsider
Arun Kumar Pillai9.44%22,982,529$10.02MInsider
Pankaj Mohan3.40%8,285,115$3.61MInsider
Syntone Ventures LLC0.70%1,705,438$743.57kInsider
Jeff Evanson0.33%808,459$352.49kInsider
Terry Dagnon0.27%653,058$284.73kInsider
Kurt J. Hilzinger0.17%423,655$184.71kInsider
Scott A. Canute0.10%246,342$107.41kInsider

1 of 3

OTLK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OTLK0.01%96.28%Net BuyingNet Buying
IMUX0.05%99.95%
AVXL0.04%4.79%
NBP0.01%12.16%Net BuyingNet Selling
HURA0.01%33.05%

Outlook Therapeutics Stock Ownership FAQ

Who owns Outlook Therapeutics?

Outlook Therapeutics (NASDAQ: OTLK) is owned by 0.01% institutional shareholders, 96.28% Outlook Therapeutics insiders, and 3.71% retail investors. Ghiath M. Sukhtian is the largest individual Outlook Therapeutics shareholder, owning 116.76M shares representing 47.96% of the company. Ghiath M. Sukhtian's Outlook Therapeutics shares are currently valued at $50.91M.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.